# Seal, Stopping Eczema and Allergy Study

> **NCT03742414** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kari Nadeau, MD, PhD** · enrollment: 398 (actual)

## Conditions studied

- Eczema, Infantile
- Eczema
- Atopic Dermatitis Eczema
- Atopic Dermatitis

## Interventions

- **COMBINATION_PRODUCT:** Tri-lipid skin barrier cream (Epiceram)
- **COMBINATION_PRODUCT:** Fluticasone propionate Cream 0.05%
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT03742414
- **Lead sponsor:** Kari Nadeau, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-30
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742414, "Seal, Stopping Eczema and Allergy Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03742414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*